Alkermes, Inc. http://www.alacrastore.com/company-snapshot/Alkermes_Inc-1052488 Sunday, November 23, 2008 4:40:00 AM 1052488 Alkermes, Inc. en AlacraStore RSS Builder 1.0 30 http://www.alacrastore.com/storecontent/ccbn/B2013869ccbn/B2013869norm...Moving forward, Co. will continue to manage the business with discipline, while investing in opportunities for long-term growth. ... 11/6/2008 9:07:00 PMAlkermes, Inc.54.0000EditedAlkermes, Inc. Q2 2009 Earnings Conference Call SummaryALKS4:30pm ETBriefB2013869Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/newstex/BW-0001-29319781newstex/BW-0001-29319781xml Nov. #, #### (Business Wire) -- Alkermes, Inc. (NASDAQ: ALKS) today announced financial results for its second quarter of fiscal ####. Financial highlights for the quarter ended September ##, #### include: A profitable quarter on...090000000901500004000000040160000401604804016001040160180401600304016047040020000400200607000000070140000701401211/6/2008 5:29:28 PM1800000018008000180040001802000018012000Business WireBW-0001-29319781ALKERMES INCJOHNSON & JOHNSONJAMES M FRATESALKSJNJNewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/T2013869ccbn/T2013869norm...Ladies and gentlemen, thank you for standing by. Welcome to the Alkermes conference call to discuss the Company's second quarter financial results for fiscal ####. (OPERATOR INSTRUCTIONS). Please be advised that this call is being taped at Alkermes' request. Now, I would like to introduce your host for today's call, Ms. Rebecca Peterson, Vice President of Corporate Communications at Alkermes. Ma'am, you may begin. ... 11/6/2008 5:07:00 PMAlkermes, Inc.54.0000FinalAlkermes, Inc. Q2 2009 Earnings Conference Call TranscriptALKS4:30pm ETTranscriptT2013869Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/newstex/BW-0001-29082625newstex/BW-0001-29082625xml Oct. ##, #### (Business Wire) -- Alkermes, Inc. (NASDAQ: ALKS) will host a conference call at #:## p.m. EST on Thursday, November #, #### to discuss the companya€™s financial results for its second quarter of fiscal ####. Management...0400000004016000040160480401601810/30/2008 5:26:28 PM180000001800800018004000Business WireBW-0001-29082625ALKERMES INCALKSNewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/B1915039ccbn/B1915039norm...Profitable qtr., driven by manufacturing and royalty revenues for RISPERDAL CONSTA and previously announced payment from Lilly. ... 8/7/2008 8:05:00 PMAlkermes, Inc.54.0000EditedAlkermes, Inc. Q1 2009 Earnings Conference Call SummaryALKS4:30pm ETBriefB1915039Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1915039ccbn/T1915039norm...Ladies and gentlemen, thank you for standing by. Welcome to the Alkermes conference call to discuss the Company's first-quarter financial results for fiscal ####. At this time all participants are in a listen-only mode. (OPERATOR INSTRUCTIONS). Please be advised that this call is being taped at Alkermes' request. Now I would like to introduce your host for today's call, Ms. Rebecca Peterson, Vice President of Corporate Communications at Alkermes. Please go ahead. ... 8/7/2008 6:05:00 PMAlkermes, Inc.54.0000FinalAlkermes, Inc. Q1 2009 Earnings Conference Call TranscriptALKS4:30pm ETTranscriptT1915039Credit & Investment ResearchThomson StreetEventsUS - In June ####, the board of Alkermes Inc, a biotechnology company, authorized the repurchase of up to $## mil of the company's common stock outstanding in open market or privately negotiated transactions.6/18/2008 2:50:13 PM01642T01642T01642T01642TAlkermes IncAlkermes IncAlkermes IncAlkermes Inchttp://www.alacrastore.com/storecontent/Thomson_M%26A/Alkermes_Inc_buys_back_stock-1987516020sdc/19875160201987516020Copyright © 2008, Thomson Financial, All Rights ReservedNasdaqDrugsUnited StatesBiological products, except diagnostic substances2836MAMassachusettsPublicALKS2836:Biological products, except diagnostic substances8071:Medical laboratories8731:Commercial physical and biological research8733:Noncommercial research organizations2836:Biological products, except diagnostic substances8071:Medical laboratories8731:Commercial physical and biological research8733:Noncommercial research organizationsNasdaqDrugsUnited StatesBiological products, except diagnostic substances2836MAMassachusettsPublicALKS162973001Biotech coBiotech coCashCash OnlyCommon Stock162973001Jun 18 20083.19800341.3050027.4020027.4020022.5330026.04000-46.17800-86.19500305.314000.535000.5250015.264001.62000166.97900172.83000240.717000.04700656.311000.000000.000000.000000.000000.000000.0000031 Mar 0831 Mar 0831 Mar 0731 Mar 0631 Mar 0531 Mar 041.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.00000Alkermes Inc, located inCambridge, Massachusetts, abiotechnology company focusedon products based onproprietary, extended-releaseand pulmonary drug deliverytechnologies for widespreaddiseases such as centralnervous system disorders,addiction, and diabetes. Itsproducts currently on themarket include Vivitrol andRisperdal Consta. The companywas founded in 1987.Alkermes Inc, located in Cambridge, Massachusetts, abiotechnology company focused on products based onproprietary, extended-release and pulmonary drug deliverytechnologies for widespread diseases such as central nervoussystem disorders, addiction, and diabetes. Its productscurrently on the market include Vivitrol and RisperdalConsta. The company was founded in 1987.Alkermes Inc, located in Cambridge, Massachusetts, a biotechnology company focused on products based on proprietary, extended-release and pulmonary drug delivery technologies for widespread diseases such as central nervous system disorders, addiction, and diabetes. Its products currently on the market include Vivitrol and Risperdal Consta. The company was founded in 1987.1.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.0000014.00000Alkermes Inc, located inCambridge, Massachusetts, abiotechnology company focusedon products based onproprietary, extended-releaseand pulmonary drug deliverytechnologies for widespreaddiseases such as centralnervous system disorders,addiction, and diabetes. Itsproducts currently on themarket include Vivitrol andRisperdal Consta. The companywas founded in 1987.Alkermes Inc, located in Cambridge, Massachusetts, abiotechnology company focused on products based onproprietary, extended-release and pulmonary drug deliverytechnologies for widespread diseases such as central nervoussystem disorders, addiction, and diabetes. Its productscurrently on the market include Vivitrol and RisperdalConsta. The company was founded in 1987.Alkermes Inc, located in Cambridge, Massachusetts, a biotechnology company focused on products based on proprietary, extended-release and pulmonary drug delivery technologies for widespread diseases such as central nervous system disorders, addiction, and diabetes. Its products currently on the market include Vivitrol and Risperdal Consta. The company was founded in 1987.0.000000.000000.00000100.69000NU.S. Dollar16 Jun 08Mon, 16 Jun 2008 00:00:00 ESTDate Announced: 06/16/2008Date Effective:BuybackNot Appl.0.000000.000000.000000.000000.000000.00000Price/Share0.0000040 U.S. Dollar40.000000.0000040 U.S. Dollar40.000000.000000.000000.000000.000000.0000040 U.S. Dollar1.00000N20.378000.000000.000000.000000.000000.0000040.0000040.000000.000000.000000.000000.000000.000004.240000.000000.000000.000000.000000.000000.000000.0000013.124000.000000.000000.0000011.9000012.3600013.560002.582000.000000.344000.00000536.396000.00000160.324001365.33200305.31400151.6390030.29600561.322000.000001.000002.000003.000004.000005.000006.000007.000008.00000US - In June 2008, the boardof Alkermes Inc, abiotechnology company,authorized the repurchase ofup to $40 mil of the company'scommon stock outstanding inopen market or privatelynegotiated transactions.US - In June 2008, the board of Alkermes Inc, a biotechnology company, authorized the repurchase of up to $40 mil of the company's common stock outstanding in open market or privately negotiated transactions.US - In June 2008, the board of Alkermes Inc, a biotechnology company, authorized therepurchase of up to $40 mil of the company's common stock outstanding in open market orprivately negotiated transactions.US - In June 2008, the board of Alkermes Inc, a biotechnology company, authorized the repurchase of up to $40 mil of the company's common stock outstanding in open market or privately negotiatedtransactions.US - In June 2008, the board of Alkermes Inc, a biotechnology company, authorized the repurchase of up to $40 mil of the company's commonstock outstanding in open market or privately negotiated transactions.Intended0.000000.000000.000000.000003.1980027.4020027.4020022.5330026.04000-46.17800-86.19500305.3140015.264001.620000.090000.04000-0.82000-1.250001.62000305.31400305.31400203.4610048.2160034.11200105.93000166.979009.445003.81800-73.91600-102.38500166.97900172.8300010.543003.81800-73.91600-102.38500172.83000240.71700239.96500166.6010076.1260039.05400240.71700656.31100656.31100568.62100477.16300338.87400270.03000Status:IntendedUS-999.00000np0.71800-999.00000np572.809000.0000054.6910020.2030057.56500305.3140017.2790024.860000.000000.000000.000002836:Biological products, except diagnostic substances8071:Medical laboratories8731:Commercial physical and biological research8733:Noncommercial research organizations162973001NasdaqUnited States2836MassachusettsPublicALKS2836:Biological products, except diagnostic substances8071:Medical laboratories8731:Commercial physical and biological research8733:Noncommercial research organizations162973001NasdaqUnited States2836MassachusettsPublicALKS40.0000040.0000040.0000020.37800Deal InformationTF Mergers & Acquisitionshttp://www.alacrastore.com/storecontent/ccbn/B1854277ccbn/B1854277norm...Signed an agreement with J&J for development and commercialization of a four-week formulation of RISPERDAL CONSTA. ... 5/22/2008 8:05:00 PMAlkermes, Inc.54.0000EditedQ4 2008 Alkermes, Inc. Earnings Conference Call SummaryALKS4:30pm ETBriefB1854277Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1854277ccbn/T1854277norm...Ladies and gentlemen, thank you for standing by. Welcome to the Alkermes conference call to discuss the Company's fiscal year #### financial results. At this time, all participants are in a listen-only mode. There will be a question and answer session to follow. Please be advised that this call is being taped at Alkermes' request. At this time, I would like to introduce you to your host for today's call, Ms. Rebecca Peterson, Vice President of Corporate Communications at Alkermes. Please go ahead. ... 5/22/2008 6:05:00 PMAlkermes, Inc.54.0000FinalQ4 2008 Alkermes, Inc. Earnings Conference Call TranscriptALKS4:30pm ETTranscriptT1854277Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/B1756098ccbn/B1756098normQ# #### Alkermes, Inc. Earnings Conference Call2/7/2008 8:06:00 PMAlkermes, Inc.54.0000EditedQ3 2008 Alkermes, Inc. Earnings Conference Call SummaryALKS4:30pm ETBriefB1756098Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1756098ccbn/T1756098normQ# #### Alkermes, Inc. Earnings Conference Call2/7/2008 7:06:00 PMAlkermes, Inc.54.0000FinalQ3 2008 Alkermes, Inc. Earnings Conference Call TranscriptALKS4:30pm ETTranscriptT1756098Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1745166ccbn/T1745166normAlkermes, Inc. at Merrill Lynch ##th Global Pharmaceutical, Biotechnology & Medical Device Conference2/5/2008 10:06:00 PMAlkermes, Inc.54.0000FinalAlkermes, Inc. at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference TranscriptALKS4:00pm ETTranscriptT1745166Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1731874ccbn/T1731874norm1/9/2008 4:05:00 PMAlkermes, Inc.54.0000FinalAlkermes, Inc. at JPMorgan Healthcare Conference TranscriptALKS9:30am PT... - JPMorgan - AnalystGood morning. My name is Cory Kasimov, and I'm a senior biotech analyst here at JPMorgan and it's my pleasure to introduce Alkermes, the next company to present to us here today. Alkermes is focused on developing products utilizing its extended release and pulmonary drug delivery technologies, which, importantly, have been validated by multiple partnerships, not to mention multiple regulatory approvals. Alkermes diabetes portfolio is currently of particular interest to investors. This includes once weekly exenatide, which is partnered with Amylin and Eli Lilly and recently generated a press impressive Phase III data; and also AIR insulin, which is also partnered with Eli Lilly and set to produce Phase III data in ####. Here to present for Alkermes is David Broecker, President and CEO. Also, please note that the breakout session will take place in the Yorkshire Room after his presentation. So with that, David? ... TranscriptT1731874Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T1713888ccbn/T1713888norm1/4/2008 3:06:00 PMAlkermes, Inc.54.0000FinalAlkermes, Inc. at Morgan Stanley Pharmaceutical CEOs Unplugged Conference TranscriptALKS11:00am ET... - Morgan Stanley - AnalystI'm very happy to introduce Richard Pops, Chairman of Alkermes. Richard has -- I guess you've been here -- we're very delighted to have you today. What I thought we would do in terms of where to start with all the questions, Alkermes and Amylin stocks took a big beating after what we thought was pretty good data on BYETTA LAR. That wasn't the market's take. So I am wondering if you could talk about your view of the data and what you think the market is missing. ... TranscriptT1713888Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/srp/18939srp/18939norm... #####-#### Incorporated:PennsylvaniaWeb Site: www.alkermes.comSIC Classification: Pharmaceutical Preparations (####) Business Description: Alkermes, Inc. is a pharmaceutical company that develops products based on sophisticated drug delivery technologies to enhance therapeutic outcomes in major diseases. Indices:Russell ####, Russell #### ... 1893901642T108ALKS10/6/2006 12:37:00 PM18939Credit & Investment ResearchSharkRepellent.net